Anixa Biosciences Inc financial data

Symbol
ANIX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3150 Almaden Expressway, Suite 250, San Jose, CA
State of incorporation
DE
Fiscal year end
October 31
Former names
ITUS Corp (to 9/27/2018), COPYTELE INC (to 8/27/2014)
Latest financial report
10-Q - Q2 2024 - Sep 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.32K % -21.4%
Debt-to-equity 8.38 % +25.6%
Return On Equity -54.8 % -36.5%
Return On Assets -50.4 % -34.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.2M shares +3.57%
Common Stock, Shares, Outstanding 32.1M shares +3.64%
Entity Public Float 121M USD +29.3%
Common Stock, Value, Issued 321K USD +3.55%
Weighted Average Number of Shares Outstanding, Basic 32.1K shares +3.49%
Weighted Average Number of Shares Outstanding, Diluted 32.1K shares +3.49%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 210K USD
Revenue from Contract with Customer, Excluding Assessed Tax 210K USD
Research and Development Expense 6.54M USD +35%
General and Administrative Expense 7.18M USD +5.97%
Costs and Expenses 13.7M USD +16.5%
Operating Income (Loss) -13.7M USD -18.6%
Net Income (Loss) Attributable to Parent -12.4M USD -16.6%
Earnings Per Share, Basic 0.29 USD/shares -59.7%
Earnings Per Share, Diluted 0.29 USD/shares -25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.23M USD -61.7%
Cash, Cash Equivalents, and Short-term Investments 20.7M USD
Assets, Current 22.7M USD -14.1%
Operating Lease, Right-of-Use Asset 238K USD +33.7%
Assets 22.9M USD -13.8%
Accounts Payable, Current 302K USD +221%
Accrued Liabilities, Current 1.68M USD -1.99%
Liabilities, Current 2M USD +7.92%
Operating Lease, Liability, Noncurrent 213K USD +56.6%
Liabilities 2.22M USD +11.2%
Retained Earnings (Accumulated Deficit) -238M USD -5.48%
Stockholders' Equity Attributable to Parent 21.8M USD -14.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 20.7M USD -15.8%
Liabilities and Equity 22.9M USD -13.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.31M USD -16.1%
Net Cash Provided by (Used in) Financing Activities 2.26M USD
Net Cash Provided by (Used in) Investing Activities 129K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 32.1M shares +3.64%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 83K USD
Deferred Tax Assets, Valuation Allowance 34.5M USD +16.6%
Deferred Tax Assets, Gross 34.5M USD +16.6%
Operating Lease, Liability 237K USD +26.7%
Lessee, Operating Lease, Liability, to be Paid 324K USD +47.9%
Operating Lease, Liability, Current 24K USD -52.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 63K USD -10%
Lessee, Operating Lease, Liability, to be Paid, Year One 56K USD -16.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 87K USD +172%
Lessee, Operating Lease, Liability, to be Paid, Year Three 65K USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 19.9K shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 66K USD
Additional Paid in Capital 259M USD +3.43%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 100 USD/shares 0%